HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McNeil Proposes Tylenol Label Change To Keep 1,000-MG Dose Available OTC

This article was originally published in The Tan Sheet

Executive Summary

In a bid to keep 500-mg tablets and 1,000-mg doses of acetaminophen available over the counter, McNeil Consumer Healthcare argues revised dosing instructions would address the root cause of unintentional overdose without unduly restricting access to the popular painkiller

You may also be interested in...



McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.

Glaxo Acetaminophen Efficacy Studies Fill FDA's 1,000-MG Dose Data Gaps

GlaxoSmithKline generated clinical data supporting the greater pain-relief efficacy of 1,000 mg of acetaminophen over 500-mg and 650-mg doses, urging FDA to maintain OTC status for the high dose.

McNeil Exec Calls For Uniform Use Of "Acetaminophen" Name

Requiring all acetaminophen product labels to include the drug name, not an abbreviation, will help assure consumers know when an OTC or Rx drug contains the ingredient, says an executive with the manufacturer of the market-leading Tylenol line

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS136408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel